About
Frazier Life Sciences Acquisition Corp II
Frazier Life Sciences Acquisition Corp II focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2026 and is based in Palo Alto, California.
The company profile, business description, and key company details are provided by S&P Global Market Intelligence. The list of executives is sourced from SEC.gov. Recent SEC filings are sourced directly from SEC.gov.
Frazier Life Sciences Acquisition Corp II Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:FLSC
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $10.28 | $10.28 | $10.16 | $10.17 | $10.17 | -0.11 | 3,800 |
| 2026-10-29 | $10.19 | $10.28 | $10.18 | $10.21 | $10.21 | +0.02 | 2,400 |
| 2026-10-28 | $10.23 | $10.23 | $10.23 | $10.23 | $10.23 | 0.00 | 0 |
| 2026-10-27 | $10.21 | $10.28 | $10.21 | $10.23 | $10.23 | +0.02 | 4,000 |
| 2026-10-26 | $10.25 | $10.30 | $10.10 | $10.28 | $10.28 | +0.03 | 28,800 |
| 2026-10-23 | $10.30 | $10.32 | $10.27 | $10.30 | $10.30 | 0.00 | 20,000 |
| 2026-10-22 | $10.35 | $10.37 | $10.25 | $10.27 | $10.27 | -0.08 | 28,300 |
| 2026-10-21 | $10.30 | $10.37 | $10.28 | $10.30 | $10.30 | 0.00 | 45,200 |
| 2026-10-20 | $10.29 | $10.35 | $10.26 | $10.28 | $10.28 | -0.01 | 71,700 |
| 2026-10-19 | $10.40 | $10.63 | $10.29 | $10.29 | $10.29 | -0.11 | 142,100 |
| 2026-10-16 | $10.59 | $10.59 | $10.28 | $10.35 | $10.35 | -0.24 | 51,700 |
| 2026-10-15 | $10.23 | $10.50 | $10.23 | $10.49 | $10.49 | +0.26 | 84,200 |
| 2026-10-14 | $10.18 | $10.41 | $10.18 | $10.29 | $10.29 | +0.11 | 1,217,900 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Oct 27, 2026 | Filing |
| 8-K | Oct 22, 2026 | Current Report |
| SCHEDULE 13G | Oct 22, 2026 | Filing |
| SCHEDULE 13D | Oct 21, 2026 | Filing |
| SCHEDULE 13G | Oct 21, 2026 | Filing |
| SCHEDULE 13G | Oct 21, 2026 | Filing |
| SCHEDULE 13G | Oct 16, 2026 | Filing |
| 8-K | Oct 15, 2026 | Current Report |
| 424B4 | Oct 14, 2026 | Prospectus |
| EFFECT | Oct 13, 2026 | Notice of Effectiveness |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Albert Cha, M.D., Ph.D.
Chief Executive Officer and Director
Fran Adams
Chief Financial Officer
Kevin Li, M.D.
Chief Business Officer
Ali Jackson, J.D.
General Counsel
William C. Fairey, Jr.
Director
Benjamin L. Palleiko
Director, Chairman
R. Scott Struthers, Ph.D.
Director
